EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prospective ICH Q2(R2)-Aligned Total-Error Validation of Label-Free Untargeted Proteomics for Host Cell Protein Quantification in Biotherapeutics

Somar Khalil iD, Jean-François Dierick iD, Pascal Bourguignon, Michel Plisnier

Proteomes · 23.04.2026 · 14 (2) · 21

DOI: 10.3390/proteomes14020021 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proteomes, online erschienen am 23.04.2026. Verfasst von Somar Khalil und 3 weiteren Autor:innen. Beteiligte Einrichtung: Technical Research & Development, GSK, 1330 Rixensart, Belgium. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Untargeted proteomics enables quantitative host cell protein (HCP) determination in biotherapeutics, yet no workflow has been validated under ICH Q2(R2) for regulated quality control.

Methods

A prospective total-error (TE) validation of label-free ddaPASEF proteomics was performed. A stable isotope-labeled whole-proteome standard was spiked into NISTmAb at seven levels (20–80 ng) and analyzed in four independent assays (198 injections), supporting one-way random-effects ANOVA with Welch–Satterthwaite adjustment. Peptide-level identification error was evaluated by dual entrapment.

Results

Empirical false-discovery proportions were below 1% at q = 0.01. Weighted least-squares regression (R2 = 0.993) confirmed stable proportional compression with 81–85% recovery. Repeatability dominated the variance structure (median CV 2.7%); intermediate precision SD ranged from 0.69% to 3.81%. Both 95% β-expectation and 95/95 content tolerance intervals were contained within ±30% at all levels, defining a validated range of 20–80 ng. Abundance-stratified TE profiling revealed concentration-dependent calibration heterogeneity, with stratum-specific intervals within ±35% defining an abundance-aware LLOQ of 3.6 ppm (P95 = 3.87 ppm). Robustness under independent search software (FragPipe v24.0, CCC = 0.998) and cross-platform acquisition (Astral, CCC = 0.980) remained within ±30% limits.

Conclusions

This constitutes the first prospective ICH Q2(R2)-aligned validation of untargeted proteomics for HCP quantification, with a transferable statistical framework for high-dimensional analytical methods.

Schlagwörter

Stichwörter der Autor:innen

ICH Q2(R2)LC-MS/MSaccuracy profileanalytical validationddaPASEFhost cell proteinslabel-free quantificationtotal error

Autor:innen und Institutionen

  • Technical Research & Development, GSK, 1330 Rixensart, Belgium.

ORCID-Profile: Somar Khalil, Jean-François Dierick

Zitieren

APA

Khalil, S., Dierick, J. F., Bourguignon, P., & Plisnier, M. (2026). Prospective ICH Q2(R2)-Aligned Total-Error Validation of Label-Free Untargeted Proteomics for Host Cell Protein Quantification in Biotherapeutics. Proteomes, 14(2), 21. https://doi.org/10.3390/proteomes14020021

Vancouver

Khalil S, Dierick JF, Bourguignon P, Plisnier M. Prospective ICH Q2(R2)-Aligned Total-Error Validation of Label-Free Untargeted Proteomics for Host Cell Protein Quantification in Biotherapeutics. Proteomes. 2026;14(2):21. doi:10.3390/proteomes14020021

BibTeX
@article{Khalil2026,
  author = {Khalil, Somar and Dierick, Jean-François and Bourguignon, Pascal and Plisnier, Michel},
  title = {Prospective ICH Q2(R2)-Aligned Total-Error Validation of Label-Free Untargeted Proteomics for Host Cell Protein Quantification in Biotherapeutics},
  journal = {Proteomes},
  year = {2026},
  volume = {14},
  number = {2},
  pages = {21},
  doi = {10.3390/proteomes14020021}
}
Kostenlos starten →